Skip to content
value.today

Arterys Inc

Formerly Morpheus Medical, Inc.

Total raised
$62 M
3 rounds on record
Latest round
$24 M
Apr 2020
First round on record
Nov 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Arterys Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2020$24 MNo. 3$10 to $50 million

Arterys Inc: Raise no. 3, Apr 2020

Investors in this round

15 investors had bought by the notice of May 12, 2020: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $27 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Axerio-Cilies · Executive Officer, Director
  • Tim Henn · Executive Officer
  • David Rosa · Director
  • Henry Weinstein · Director
  • Khush Mehta · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Sale of Series C Preferred Stock, Series C-1 Preferred Stock and Common Stock issuable upon conversion. $9,402,613.39 of the Total Amount Sold was conversion of outstanding debt.”
  • On the use of proceeds: “Proceeds will be used for general corporate purposes including, but not limited to, executive salaries.”

Signed by Tim Henn, Cfo. Source: SEC Form D, newest notice filed May 12, 2020. Read the notice at the SEC.

equitySEC
Nov 2017$30 MNo. 2$10 to $50 million

Arterys Inc: Raise no. 2, Nov 2017

Investors in this round

24 investors had bought by the notice of Nov 17, 2017: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale of Series B and Series B-1 Preferred Stock; Common Stock issuable upon conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fabien Beckers · Executive Officer, Director
  • John Axerio-Cilies · Executive Officer, Director
  • Dave Rosa · Director
  • Robert Brownell · Director
  • Steve Dow · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for general corporate purposes, including, but not limited to, executive salaries.”

Signed by Fabien Beckers, Ceo. Source: SEC Form D, newest notice filed Nov 17, 2017. Read the notice at the SEC.

equitySEC
Nov 2015$7 MNo. 1$2 to $10 million

Arterys Inc: Raise no. 1, Nov 2015

Investors in this round

23 investors had bought by the notice of Dec 10, 2015: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $18 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale of Series A Preferred Stock; Common Stock issuable upon conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fabien Beckers · Executive Officer, Director
  • John Axerio-Cilies · Executive Officer, Director
  • Robert Brownell · Director
  • Steve Dow · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for general corporate purposes, including, but not limited to, executive salaries.”

Signed by Fabien Beckers, Ceo. Source: SEC Form D, newest notice filed Dec 10, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Arterys Inc chose not to state its revenue in its newest notice of a funding round (May 2020).

    SEC Form D · May 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · May 2020

That is all the official record says: Arterys Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Arterys Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arterys Inc
NameRoleNamed in
John Axerio-CiliesExecutive officerMay 2020
Tim HennExecutive officerMay 2020
Fabien BeckersExecutive officerNov 2017
David RosaDirectorMay 2020
Henry WeinsteinDirectorMay 2020
John Axerio-CiliesDirectorMay 2020
Khush MehtaDirectorMay 2020
Dave RosaDirectorNov 2017
Fabien BeckersDirectorNov 2017
Robert BrownellDirectorNov 2017
Steve DowDirectorNov 2017